In fact, TSN was not only able to sensitize NSCLC cells to TRAIL, but was also able to increase sensitivity to adriamycin at sub-toxic concentrations in breast cancer cells (unpublished observation) and increase sensitivity to a PD-L1 antagonist in melanoma cells (unpublished observation). This evidence concerns the gene CD274 and breast cancer.